Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects

Aims Free fatty acids (FFA) can act as direct signalling molecules through activation of several membrane‐bound G‐protein coupled receptors. The FFA2 receptor (known as GPR43) is activated by short chain fatty acids (SCFA) such as acetate and has been shown to play a major role in SCFA‐induced neutr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of clinical pharmacology Jg. 82; H. 1; S. 139 - 148
Hauptverfasser: Namour, Florence, Galien, René, Van Kaem, Tim, Van der Aa, Annegret, Vanhoutte, Frédéric, Beetens, Johan, Klooster, Gerben
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England John Wiley and Sons Inc 01.07.2016
Schlagworte:
Adolescent
Adult
Butyrates - administration & dosage
Butyrates - pharmacokinetics
Butyrates - pharmacology
Cell Movement - drug effects
Dose-Response Relationship, Drug
Double-Blind Method
FFA2
GLPG0974
GPR43
healthy subjects
Humans
Male
Middle Aged
Neutrophil Activation - drug effects
Pharmacokinetic Dynamic Relationships
Receptors, Cell Surface - antagonists & inhibitors
safety
Thiophenes - administration & dosage
Thiophenes - pharmacokinetics
Thiophenes - pharmacology
Young Adult
FFA2
PD
healthy subjects
GPR43
safety
PK
GLPG0974
ISSN:0306-5251, 1365-2125
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Free fatty acids (FFA) can act as direct signalling molecules through activation of several membrane‐bound G‐protein coupled receptors. The FFA2 receptor (known as GPR43) is activated by short chain fatty acids (SCFA) such as acetate and has been shown to play a major role in SCFA‐induced neutrophil activation and migration and to contribute in the development and control of inflammation. GLPG0974 is a potent and selective antagonist of the human FFA2. The main objectives of the two phase 1 trials were to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of GLPG0974. Methods Two consecutive randomized, double‐blind, placebo‐controlled, single centre trials in healthy subjects were performed. In the first, GLPG0974 was administered as single doses up to 250 mg and in the second, multiple daily doses up to 400 mg for 14 days were evaluated. Non‐compartmental analysis was used to determine GLPG0974 pharmacokinetics while target engagement was investigated through the inhibition of neutrophils in acetate‐simulated whole blood samples using surface expression of CD11b activated epitope as a marker of neutrophil activation. Results The investigation of safety/tolerability and pharmacokinetics in the early development phase showed that GLPG0974 was safe and well tolerated up to a daily dose of 400 mg. GLPG0974 showed good and dose proportional exposure up to 400 mg daily as well as a substantial and sustained inhibition of acetate‐stimulated neutrophil activation. Conclusion Based on these results, a proof‐of‐concept study was initiated to evaluate the safety, tolerability and efficacy of GLPG0974 in patients with mild to moderate ulcerative colitis.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.12900